Rapha Capital Management
Venture Capital, Private equity
Active
Surfside, United States
8
26M
4
1.33
0.50
2
- Areas of investment
Summary
The fund is constantly included in less than 2 deals per year. The top activity for fund was in 2018. Deals in the range of 50 - 100 millions dollars are the general things for fund.
Among the most popular portfolio startups of the fund, we may highlight AsclepiX Therapeutics, Poseida Therapeutics. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Genetics.
Besides them, we counted 1 critical employee of this fund in our database.
The usual cause for the fund is to invest in rounds with 7 partakers. Despite the Rapha Capital Management, startups are often financed by Malin Corporation, Vivo Capital, Tavistock Life Sciences. The meaningful sponsors for the fund in investment in the same round are Vivo Capital, TEDCO, Salem Partners.
Investor highlights
- Industry focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 8
- Lead investments
- 0
- Exits
- 2
- Rounds per year
- 1.33
- Follow on index
- 0.50
- Investments by industry
- Biotechnology (4)
- Therapeutics (4)
- Health Care (4)
- Health Diagnostics (3)
- Pharmaceutical (3) Show 2 more
- Investments by region
-
- United States (7)
- Israel (1)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 247M
- Group Appearance index
- 0.62
- Avg. company exit year
- 0
- Avg. multiplicator
- 2.32
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| AsclepiX Therapeutics | 26 Jul 2023 | Biotechnology, Health Diagnostics, Therapeutics | Early Stage Venture | 10M | United States, Maryland, Baltimore |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.